Mesoblast lining up partners for stem cell trials – Business Spectator
The Australian Financial Review |
Mesoblast lining up partners for stem cell trials
Business Spectator Mesoblast's 30-patient trial found an injection of the company's MPC-300-IV product, an allogeneic mesenchymal precursor cell, was safe and improved organ function. The Melbourne-based company presented the results in poster form at the annual … Mesoblast eyes pharma deals after diabetes trial success Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And … |
